PELP1 and cancer: CBP/p300, p/CAF, the p160 family, PELP1, SWI/SNF complex, YAP, and PARP-1 identified as ERα co-activators lead to chromatin de-condensation and modulate epigenetic changes, providing a selective advantage for cancer cell growth, differentiation, invasion, metastasis, and endocrine resistance (Gadad et al, 2021; Garcia-Martinez et al, 2021; Ju et al, 2006; Schiewer and Knudsen, 2014; Zhu et al, 2019).